Stade Français become the first professional Rugby club to sign a commercial agreement with PolarCool AB.

Stade Français become the first French Rugby Top14 club to sign a commercial agreement with PolarCool AB (publ) for use of the PolarCap® System. The agreement will last for two years and marks an important breakthrough for PolarCool within both the French market and the sport of Rugby. The agreement follows a successful 6-week evaluation period and marks a substantial commercial value for PolarCool.

Stade Français´ Medical Chief, Dr Elliot Rubio, has been impressed with the systems effects on treating Stade Français players, as well as the players positive responses when using and after using the device. Dr Elliot Rubio has also been instrumental in generating interest for PolarCap® within other French Top 14 clubs.

Dr Elliot Rubios comments:

– After a successful trial of the PolarCap® System, I am encouraged by the systems benefits and effects on players suffering from concussion. I am grateful to Stade Français Paris for the opportunity to use the device long term and proud to be the first rugby organization in France to provide the PolarCap® System to its players.

PolarCool’s CEO Erik Andersson comments:

– It is gratifying that PolarCool has signed its first commercial agreement in professional rugby. The positive effects of PolarCap® have been confirmed for Stade Français’ medical team. This is crucial for our business which is built on clinical evidence. We are looking forward to exploring the new opportunity on the French market.

PolarCool AB (publ) has also signed evaluation agreements with Top 14 clubs Biarritz Olympique Pays Basque and ASM Clermont Auvergne. The agreements have generated considerable interest across French Rugby, with Top14 and ProD2 clubs approaching PolarCool.

This information is information that PolarCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on December 6th, 2021.

 For more information

Erik Andersson –  CEO PolarCool AB (publ)               
+46 – 738 60 57 00                                         
E-mail: erik.andersson@polarcool.se
 

About PolarCool AB (publ)

PolarCool AB (publ) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System. PolarCool AB (publ) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.